Is in vitro-acquired resistance to enzalutamide a useful model?

Prostate cancer is a major health concern among men worldwide, with an estimated 234,460 new cases diagnosed and 27,350 deaths in the USA alone in 2006 [1]. Significant advancements have been achieved in the fight against this deadly disease, both in terms of secondary prevention [2] and in the management of advanced prostate cancer resistant to castration [3], namely, castration-resistant prostate cancer (CRPC). Overdiagnosis is a major drawback of screening, and demands patient informed consent, careful selection of patients to biopsy by the use of more refined tests than prostate-specific antigen (PSA) alone, such as PCA3 and prostate health index [4], as well as appropriate use of active surveillance [2].

Click here to view the full article